Division of Cardiology, Heart Failure, and Transplantation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
Can J Cardiol. 2023 Jun;39(6):853-864. doi: 10.1016/j.cjca.2023.03.014. Epub 2023 Mar 23.
In this review, we provide a comprehensive overview of the impact of the COVID-19 pandemic on adult heart transplantation. We highlight the decline in the number of adult transplantations performed throughout the pandemic as a consequence of restrictions imposed on individual programs and hospitals. There were challenges to maintaining cardiac transplant activity at multiple levels, including organ donation in intensive care units, logistical difficulties with organ procurement, and rapidly changing resource considerations at health system and jurisdictional levels. We also review the impact of COVID-19 on cardiac transplant recipients. Despite the high rates of morbidity and mortality observed during the initial phases of the pandemic among heart transplant patients infected with COVID-19, the availability of effective vaccines, pre-exposure prophylaxis, and specific antiviral therapies have drastically improved outcomes over time. Vaccines have proven to be safe and effective in reducing infections and illness severity, but specific considerations in the immunocompromised solid organ transplant population apply, including the need for additional booster doses to achieve sufficient immunisation. We further outline the strong rationale for vaccination before transplantation wherever possible. Finally, the COVID-19 response created a number of barriers to safe and efficient post-transplantation care. Given the need for frequent evaluation and monitoring, especially in the first several months after cardiac transplantation, the pandemic provided the impetus to improve virtual care delivery and explore noninvasive rejection surveillance through gene expression profiling. We hope that lessons learned will allow us to prepare and pivot effectively during future pandemics and health care emergencies.
在这篇综述中,我们全面概述了 COVID-19 大流行对成人心脏移植的影响。我们强调了由于个别项目和医院实施的限制,大流行期间进行的成人移植数量下降。在多个层面上维持心脏移植活动都存在挑战,包括重症监护病房的器官捐赠、器官采购的后勤困难,以及卫生系统和司法管辖区层面的资源考虑因素的迅速变化。我们还回顾了 COVID-19 对心脏移植受者的影响。尽管 COVID-19 感染的心脏移植患者在大流行的初始阶段观察到高发病率和死亡率,但有效的疫苗、暴露前预防和特定的抗病毒治疗的出现,随着时间的推移,大大改善了结果。疫苗已被证明在降低感染和疾病严重程度方面是安全有效的,但在免疫功能低下的实体器官移植人群中存在特定的考虑因素,包括需要额外的加强剂量以实现充分免疫。我们进一步概述了尽可能在移植前接种疫苗的强有力理由。最后,COVID-19 应对措施给安全有效的移植后护理带来了许多障碍。鉴于需要频繁评估和监测,特别是在心脏移植后的头几个月,大流行促使我们改进虚拟护理服务,并通过基因表达谱探索非侵入性排斥反应监测。我们希望吸取的经验教训将使我们能够在未来的大流行和医疗保健紧急情况中有效地做好准备和调整。